Tess O'Meara1, Anton Safonov2, David Casadevall1,3, Tao Qing1, Andrea Silber1, Brigid Killelea1, Christos Hatzis1, Lajos Pusztai4. 1. Breast Medical Oncology, Yale School of Medicine, Yale Cancer Center, 300 George St, Suite 120, Rm 133, New Haven, CT, 06520, USA. 2. University of Pennsylvania School of Medicine, Philadelphia, PA, USA. 3. Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain. 4. Breast Medical Oncology, Yale School of Medicine, Yale Cancer Center, 300 George St, Suite 120, Rm 133, New Haven, CT, 06520, USA. lajos.pusztai@yale.edu.
Abstract
PURPOSE: African-American (AA) patients with triple-negative breast cancer (TNBC) are less likely to achieve pathologic complete response from neoadjuvant chemotherapy and have poorer prognosis than Caucasian patients with TNBC, suggesting potential biological differences by race. Immune infiltration is the most consistent predictive marker for chemotherapy response and improved prognosis in TNBC. In this study, we test the hypothesis that the immune microenvironment differs between AA and Caucasian patients. METHODS: RNA-seq expression data were obtained from The Cancer Genome Atlas (TCGA) database for 162 AA and 697 Caucasian breast cancers. Estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-positive, and TNBC subtypes were included in the analyses. Tumor infiltrating lymphocyte (TIL) counts, immunomodulatory scores, and molecular subtypes were obtained from prior publications for a subset of the TNBC cases. Differences in immune cell distributions and immune functions, measured through gene expression and TIL counts, as well as neoantigen, somatic mutation, amplification, and deletion loads, were compared by race and tumor subtype. RESULTS: Immune metagene analysis demonstrated marginal immune attenuation in AA TNBC relative to Caucasian TNBC that did not reach statistical significance. The distributions of immune cell populations, lymphocyte infiltration, molecular subtypes, and genomic aberrations between AA and Caucasian subtypes were also not significantly different. The MHC1 metagene demonstrated increased expression in AA ER-positive cancers relative to Caucasian ER-positive cancers. CONCLUSIONS: This study suggests that the immunological differences between AA and Caucasian breast cancers represented by TCGA data are subtle, if they exist at all. We observed no consistent racial differences in immune gene expression or TIL counts in TNBC by race. However, this study cannot rule out small differences in immune cell subtype distribution and activity status that may not be apparent in bulk RNA analysis.
PURPOSE: African-American (AA) patients with triple-negative breast cancer (TNBC) are less likely to achieve pathologic complete response from neoadjuvant chemotherapy and have poorer prognosis than Caucasian patients with TNBC, suggesting potential biological differences by race. Immune infiltration is the most consistent predictive marker for chemotherapy response and improved prognosis in TNBC. In this study, we test the hypothesis that the immune microenvironment differs between AA and Caucasian patients. METHODS: RNA-seq expression data were obtained from The Cancer Genome Atlas (TCGA) database for 162 AA and 697 Caucasian breast cancers. Estrogen receptor (ER)-positive, humanepidermal growth factor receptor-2 (HER2)-positive, and TNBC subtypes were included in the analyses. Tumor infiltrating lymphocyte (TIL) counts, immunomodulatory scores, and molecular subtypes were obtained from prior publications for a subset of the TNBC cases. Differences in immune cell distributions and immune functions, measured through gene expression and TIL counts, as well as neoantigen, somatic mutation, amplification, and deletion loads, were compared by race and tumor subtype. RESULTS: Immune metagene analysis demonstrated marginal immune attenuation in AA TNBC relative to Caucasian TNBC that did not reach statistical significance. The distributions of immune cell populations, lymphocyte infiltration, molecular subtypes, and genomic aberrations between AA and Caucasian subtypes were also not significantly different. The MHC1 metagene demonstrated increased expression in AA ER-positive cancers relative to Caucasian ER-positive cancers. CONCLUSIONS: This study suggests that the immunological differences between AA and Caucasian breast cancers represented by TCGA data are subtle, if they exist at all. We observed no consistent racial differences in immune gene expression or TIL counts in TNBC by race. However, this study cannot rule out small differences in immune cell subtype distribution and activity status that may not be apparent in bulk RNA analysis.
Entities:
Keywords:
Genetics; Immune microenvironment; Immunotherapy; Race; Triple-negative breast cancer
Authors: Azadeh Stark; Celina G Kleer; Iman Martin; Baffour Awuah; Anthony Nsiah-Asare; Valerie Takyi; Maria Braman; Solomon E Quayson; Richard Zarbo; Max Wicha; Lisa Newman Journal: Cancer Date: 2010-11-01 Impact factor: 6.860
Authors: Volker Lennerz; Martina Fatho; Chiara Gentilini; Roy A Frye; Alexander Lifke; Dorothea Ferel; Catherine Wölfel; Christoph Huber; Thomas Wölfel Journal: Proc Natl Acad Sci U S A Date: 2005-10-24 Impact factor: 11.205
Authors: Shivani S Shinde; Michele R Forman; Henry M Kuerer; Kai Yan; Florentia Peintinger; Kelly K Hunt; Gabriel N Hortobagyi; Lajos Pusztai; W Fraser Symmans Journal: Cancer Date: 2010-11-01 Impact factor: 6.860
Authors: Damali N Martin; Brenda J Boersma; Ming Yi; Mark Reimers; Tiffany M Howe; Harry G Yfantis; Yien Che Tsai; Erica H Williams; Dong H Lee; Robert M Stephens; Allan M Weissman; Stefan Ambs Journal: PLoS One Date: 2009-02-19 Impact factor: 3.240
Authors: Francisco J Esteva; Jing Wang; Feng Lin; Jaime A Mejia; Kai Yan; Kadri Altundag; Vicente Valero; Aman U Buzdar; Gabriel N Hortobagyi; W Fraser Symmans; Lajos Pusztai Journal: Breast Cancer Res Date: 2007 Impact factor: 6.466
Authors: Julia Foldi; Adriana Kahn; Andrea Silber; Tao Qing; Emily Reisenbichler; Neal Fischbach; Justin Persico; Kerin Adelson; Anamika Katoch; Anees Chagpar; Tristen Park; Adam Blanchard; Kim Blenman; David L Rimm; Lajos Pusztai Journal: Clin Cancer Res Date: 2022-09-01 Impact factor: 13.801
Authors: Andrea Walens; Linnea T Olsson; Xiaohua Gao; Alina M Hamilton; Erin L Kirk; Stephanie M Cohen; Bentley R Midkiff; Yongjuan Xia; Mark E Sherman; Nana Nikolaishvili-Feinberg; Jonathan S Serody; Katherine A Hoadley; Melissa A Troester; Benjamin C Calhoun Journal: Lab Invest Date: 2021-02-23 Impact factor: 5.662
Authors: Gina Kim; Jessica M Pastoriza; John S Condeelis; Joseph A Sparano; Panagiota S Filippou; George S Karagiannis; Maja H Oktay Journal: Front Oncol Date: 2020-06-30 Impact factor: 6.244
Authors: Song Yao; Ting-Yuan David Cheng; Ahmed Elkhanany; Li Yan; Angela Omilian; Scott I Abrams; Sharon Evans; Chi-Chen Hong; Qianya Qi; Warren Davis; Song Liu; Elisa V Bandera; Kunle Odunsi; Kazuaki Takabe; Thaer Khoury; Christine B Ambrosone Journal: J Natl Cancer Inst Date: 2021-08-02 Impact factor: 13.506
Authors: Yara Abdou; Kristopher Attwood; Ting-Yuan David Cheng; Song Yao; Elisa V Bandera; Gary R Zirpoli; Rochelle Payne Ondracek; Leighton Stein; Wiam Bshara; Thaer Khoury; Christine B Ambrosone; Angela R Omilian Journal: Breast Cancer Res Date: 2020-06-09 Impact factor: 6.466